Anti-fibrotic program (MitoImmune Therapeutics)

N/A

Report date: 2024/11/04 15:37:47

Base Information

Drug NameAnti-fibrotic program (MitoImmune Therapeutics)
Drug Alias NameN/A
ClassificationBiologics
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsIdiopathic Pulmonary FibrosisMetabolic Dysfunction-Associated Steatotic Liver Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesMitoImmune Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesMitoImmune Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsIdiopathic Pulmonary FibrosisMetabolic Dysfunction-Associated Steatotic Liver Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A